Diffuse large B-cell lymphoma (DBCL) is the largest subgroup of non-Hodgkin's lymphomas. Primary dural lymphoma, primary skull vault lymphoma, and primary sternum lymphoma are the rare lymphomas. We present the case of a 69-year-old patient with scalp, skull, and dura involvement that accompanying sternum involvement. It should be kept in mind that in the differential diagnosis of high-grade diffuse large B-cell lymphoma in patients presenting with a mass in the skull or sternum.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869292 | PMC |
| http://dx.doi.org/10.4103/ajns.AJNS_246_19 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Extracorporeal Membrane Oxygenation (ECMO) serves as a crucial intervention for patients with severe pulmonary dysfunction by facilitating oxygenation and carbon dioxide removal. While traditional ECMO systems are effective, their large priming volumes and significant blood-contacting surface areas can lead to complications, particularly in neonates and pediatric patients. Microfluidic ECMO systems offer a promising alternative by miniaturizing the ECMO technology, reducing blood volume requirements, and minimizing device surface area to improve safety and efficiency.
View Article and Find Full Text PDFHypothermia, Hallucinations, and Atrial Fibrillation Secondary to Diffuse Large B-cell Lymphoma.
Cureus
December 2024
Emergency Medicine, Northwell Health, Manhasset, USA.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in adults, constituting a significant portion of global incidence rates. DLBCL can be further classified via genetic expression profiling into molecular subsets consisting of not-otherwise specified (NOS) subset being the most prevalent, germinal center B-cell-like (GCB) subset, and activated B-cell-like (ABC) subset. The ABC subset, marked by abnormal NF-κB signaling, is associated with poorer outcomes.
View Article and Find Full Text PDFAn integrative review of cancer-related cachexia and sarcopenia: A different focus in malignant hematology.
Health Sci Rev (Oxf)
December 2024
Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612 USA.
Introduction/background: An improved understanding of cancer-related cachexia and sarcopenia among patients with hematologic malignancies can improve their health outcomes. Patients with hematologic malignancies are affected by cancer-related cachexia and sarcopenia, but this aspect of their care is rarely studied. This review aims to increase awareness and knowledge of cancer-related cachexia and sarcopenia for patients with hematologic malignancies through a comprehensive synthesis of current research.
View Article and Find Full Text PDFSeamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination.
J Adv Pract Oncol
September 2024
St Luke's Health System - Pharmacy, Boise, Idaho.
Bispecific antibodies (BsAbs) have emerged as crucial therapeutic agents for patients with relapsed/refractory diffuse large B-cell lymphoma, multiple myeloma, and most recently, lung cancer. These therapies have demonstrated remarkable efficacy in clinical trials; however, multidisciplinary collaboration is essential to ensure optimal patient outcomes amid the operational complexities associated with BsAb therapy. As BsAbs are being prepared for broader adoption, clinicians and treatment centers must navigate operational challenges, including financial considerations, patient selection, caregiver involvement, and transitions of care.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!